Want to join the conversation?
$CELG said overall survival, a key secondary endpoint, showed no benefit with REVLIMID. Based on these results, $CELG does not currently plan to seek approval for this. REMARC evaluated maintenance therapy with REVLIMID versus placebo in diffuse large B-cell lymphoma patients on first-line rituximab plus CHOP chemotherapy induction therapy.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.